Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714843 | 0.79 | PNP (0.46) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL20748553 | 0.75 | MAP3K5 (0.37) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL316449 | 0.71 | MAPT (0.39) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6956986 | 0.70 | MAPT (0.46) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL616606 | 0.70 | MAPT (0.41) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL539263 | 0.67 | PARP1 (0.41) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL6949666 | 0.67 | MAPT (0.47) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL7922229 | 0.67 | MEN1 (0.44) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1144726 | 0.67 | MEN1 (0.44) | PNPMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL29804933 | 0.67 | MEN1 (0.44) | PNPMEN1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116362-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY | 2004-06-17 | — | — | US | claimed |
| US-10081633-B2 | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | VASADE BIOSCIENCES, INC. | 2018-09-25 | — | — | US | disclosed |
| WO-2017222946-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF | VASADE BIOSCIENCES (US) | 2017-12-28 | — | — | WO | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-6960568-B2 | Nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY (US) | 2005-10-27 | — | — | US | disclosed |
| US-20040116362-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | YALE UNIVERSITY | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239726-A1 | Novel nucleosides and related processes, pharmaceutical compositions and methods | ADAR, DCTD, ADA | PNP 12/4885MEN1 3193/4885KMT2A 1571/4885 |
| US-10081633-B2 | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | ADCY1, ADCY2, ADCY5 | PNP 288/4885MEN1 3388/4885KMT2A 4301/4885 |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | PNP 288/4885MEN1 3388/4885KMT2A 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.